An inhalable version of a single-shot, adenovirus-based viral vector vaccine might provide a new option for COVID-19 vaccination. In October 2021, the World Health Organization set a target for ...

BioNTech SE, and Moderna Inc., and an increased risk of a type of blood clot in the brain after immunization with ...

The report also includes an extensive assessment of the leading players' product portfolio and geographic presence and the key growth strategies adopted by them over the past three to four years. In ...

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the ...

Home > Pressemitteilung: HZI researchers develop RSV vaccine ... The technology based on the mouse cytomegalovirus promises long-lasting immune protection ...

Researchers review decades of progress in human cytomegalovirus (HCMV) vaccine development, emphasizing challenges, ...

Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

autologous APC vaccine pulsed ex vivo with PA2024, a recombinant fusion protein of human prostatic acid phosphatase (PAP) and GM-CSF. The final Phase III analysis is scheduled in mid 2009. Vector ...